Jack joined SV in 2019 and helps to form, fund, and guide biotechnology companies within the SV portfolio that make cutting-edge medicines.
He identifies and evaluates emerging life sciences technologies, advises early-stage portfolio companies on corporate strategy, and manages investments once publicly traded. Jack serves as a board observer at Pionyr Immunotherapeutics, Caraway Therapeutics, Catamaran Bio, and Cellinta, and as a trustee at Archemix Corporation. He has helped SV invest in Xilio Therapeutics, as well as incubate and launch Catamaran Bio, Cellinta, and Cybele Therapeutics.
Prior to joining SV, Jack was a Senior Analyst at ClearView Healthcare Partners, where he evaluated commercial opportunities to support product launch, portfolio optimization, and acquisitions for leading life sciences companies. He also played a role in the founding of the company’s analytics practice. Prior to ClearView, Jack worked within or consulted for Amicus Therapeutics, Sage Products, and MC10.
Outside of SV Jack is a proud Minnesotan who enjoys returning home to play outdoor hockey whenever possible.
BA, Chemistry and Economics, College of the Holy Cross; MS, Engineering, Science and Technology Entrepreneurship, University of Notre Dame